Class / Patent application number | Description | Number of patent applications / Date published |
424480000 | Cellulose or derivative | 81 |
20080213366 | Therapeutic Compositions - The present invention provides oral formulations of poorly bioavailable and/or poorly absorbable, and/or poorly water soluble therapeutic agents. The invention features pharmaceutical composition including a biopolymer, a therapeutic agent, for example an antimicrobial agent such as ceftriaxone, and an absorption enhancer, for example a polyoxyethylene alkyl ether absorption enhancer. Methods of making and using the pharmaceutical compositions is also described. | 09-04-2008 |
20080233192 | Tablets with Improved Dissolution Profile - The present disclosure relates to tablets obtainable by compression of a mixture comprising at least 5% by weight of a diluent and granules which comprise a very slightly soluble drug, wherein the granules consist of a core of saccharose beads having (prior to coating) a mean particle size greater than 150μ and a coating layer comprising the very slightly soluble drug and at least one film-forming substance of high-molecular weight, as well as a process for manufacturing such tablets wherein the granules consist of a core saccharose beads having (prior to coating) a mean particle size greater than 150μ and a coating layer comprising the very slightly soluble drug and at least one film-forming substance of high-molecular weight for the manufacture of tablets by compression of a mixture comprising said granules and at least 5% by weight of a diluent. | 09-25-2008 |
20080274182 | Tablet coatings made from modified carboxymethylcellulose materials - Coated tablets for the delivery of active ingredients to a user are provided. Such tablets include particular molecular weight-modified carboxymethylcellulose (CMC) coating materials either alone or in combination with other types of hydrocolloids, biogums, cellulose ethers, and the like. The utilization of such modified CMC products aids in the production of such coatings through the availability of larger amounts of base materials with lower amounts of water requiring evaporation therefrom. In such a manner, not only may dimensionally stable, non-tacky, salt tolerant, and quick dissolving edible coatings be produced, but the amount of time required for such manufacture is minimal when compared with traditional methods of production with -based materials. Furthermore, such novel edible non-digestible tablet coatings exhibit delayed dissolution beyond a user's oral cavity for tastemasking purposes, as well as protection of the tablet from environmental conditions and low tackiness properties to prevent adhesion to the user's palate. The novel method of tablet coating manufacture as well as the ultimate coated tablets exhibiting such physical characteristics are also encompassed within this invention. | 11-06-2008 |
20080305169 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds - [Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property).
| 12-11-2008 |
20080311204 | STABLE ORAL FORMULATION CONTAINING BENZIMIDAZOLE DERIVATIVE - An enteric formulation containing at least one benzimidazole compound, said formulation containing:
| 12-18-2008 |
20080317858 | FORMULATIONS OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3--2-THIOPHENECARBOXAMIDE - Provided herein are intravenous and oral formulations of N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide. Also provided are methods of making and using the formulations. | 12-25-2008 |
20090053310 | NOVEL SUSTAINED RELEASE DOSAGE FORM - The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer which provides pH-independent drug release for a considerable period of time after administration. | 02-26-2009 |
20090117186 | TROFOSFAMIDE-CONTAINING FILM-COATED TABLETS AND METHOD FOR THE PRODUCTION THEREOF - The invention at hand concerns trofosfamide containing film-coated tablets for oral application and a procedure for their production. | 05-07-2009 |
20090123543 | PHARMACEUTICAL COMPOSITIONS - A novel solid oral dosage form comprising a therapeutically effective amount of hydrophobic pharmacological active ingredient and at least one particle separating agent preferably selected from a class of wetting agents, prepared without or with minimum amount of a disintegrating agent. The hydrophobic pharmacological active ingredient active ingredient belongs to the class of angiotensin receptor blocking agents preferably is valsartan optionally in combination with hydrochlorothiazide. The active ingredient may also be a class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors preferably atorvastatin. The ratio of hydrophobic active ingredient to particle separating agent is about 20:1 to about 1:20. The process for the preparation of the novel solid oral dosage form comprises treating a hydrophobic active ingredient with at least one particle separating agent, and incorporating the treated hydrophobic active ingredient into a solid dosage form. | 05-14-2009 |
20090175941 | Tablet-form slow-release preparation for vertigo - The invention describes a pharmaceutical composition of a slow-release preparation in the form of tablets for the treatment of vertigo of any genesis. A pharmaceutical composition is described that contains cinnarizine and dimenhydrinate, wherein the release of active ingredients is slowed down. For this purpose, the pharmaceutical composition additionally contains binding agent, slow-release agent and fillers. | 07-09-2009 |
20090181086 | Rasagiline formulations, their preparation and use - Disclosed are formulations which are designed to release rasagiline mesylate while maintaining specific pharmacokinetic properties. | 07-16-2009 |
20090202637 | ORAL PHARMACEUTICAL COATED COMPOSITION FOR PULSATILE RELEASE - A pharmaceutical composition comprising a pharmaceutically active agent, a core, a coating comprising an inner film comprising cellulose acetate and hydroxypropylmethylcellulose in a ratio of cellulose acetate:hydroxypropylmethylcellulose of 80% to 99.5%:0.5% to 20% and an outer film comprising ethylcellulose and hydroxypropylcellulose in a ratio of ethylcellulose:hydroxypropylcellulose of 50% to 80%:20% to 50%. | 08-13-2009 |
20090238871 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising an ester of 4-(1-hydroxy-1-methylethyl)-2 propyl-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid characterized in that when exposed to 75% relative humidity at 40° in open dish for one month the total amount of related substances does not increase more than 1% is described. | 09-24-2009 |
20090263482 | Treatment of inflammatory bowel disease with 6-mercaptopurine - Methods of administering a delayed release 6-mercaptopurine pharmaceutical composition to patients suffering from inflammatory bowel disease which provide for release of the 6-mercaptopurine after passage of the pharmaceutical composition through the stomach are disclosed. The methods result in significant clinical improvement despite leading to very little systemic absorption of 6-mercaptopurine and also result in very few undesirable side effects. | 10-22-2009 |
20090269403 | ORAL CONTRACEPTIVE DOSAGE FORMS AND METHODS OF MAKING SUCH DOSAGE FORMS - Disclosed herein are oral dosage forms and methods of their use, in particular oral dosage systems for the delivery of drugs for use as a female oral contraceptive. In an embodiment, an oral dosage form includes a progestogen dispersed in an enteric polymer and an estrogen. | 10-29-2009 |
20090291138 | FILM-COATED PREPARATION HAVING IMPROVED STABILITY - A film-coated preparation having excellent storage stability, which contains a compound represented by the formula (I) below or a pharmacologically acceptable salt thereof, having a film layer containing one or more film coating base agents selected from polyvinyl alcohol, sodium carboxymethyl cellulose and pullulan. The formula (I) is as follows: | 11-26-2009 |
20100119602 | PHOSPHATE BINDER WITH REDUCED PILL BURDEN - The present invention is generally directed to compositions and formulations that can be used for the treatment of diseases such as End Stage Renal Disease (“ESRD”) and Chronic Renal Insufficiency (“CRI”). Specifically, it is directed to lanthanum-based compounds that bind phosphate and that can be formulated to provide for a reduced pill burden relative to other phosphate binders. In a formulation aspect of the present invention, a formulation is provided the includes a lanthanum-based, phosphate binder. The formulation is typically characterized in that in may be swallowed without chewing. Formulations of the present invention, along with a lanthanum-based compound, may optionally include the following: mass diluting agents; binders; coatings; compression/encapsulation aids; disintegrants; lubricants; plasticizers; slip/anti-electrostatic agents; powder lubricants; and, sweeteners. Where the formulation is in the form of a tablet, it typically has a volume between 0.3 cm | 05-13-2010 |
20100166861 | PHARMACEUTICAL FORMULATIONS OF SEVALAMER, OR SALTS THEREOF, AND COPOVIDONE - The present disclosure provides a pharmaceutical composition for the treatment of hyperphosphatemia in mammals. The composition includes sevelamer and copovidone. The composition is provided in the form of a coated tablet having a compressed core. Also disclosed are methods for the manufacture of such tablets, and methods for treating hyperphosphatemia in mammalian patients using the disclosed compositions. | 07-01-2010 |
20100189791 | Delayed release rasagiline malate formulation - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 07-29-2010 |
20100221338 | Coated Tablets Of 6-(5-Chloro-2-Pyridyl)-5-[(4-Methyl-1-Piperazinyl)Carbonyloxy]-7-Oxo-6,7-- Dihydro-5H-Pyrrolo[3,4-b]Pyrazine And Methods For Measuring Effectiveness Of Coating - Coated tablets of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are provided. The tablets minimize the perceived bitterness of the medicament. A method for analyzing instantaneous dissolution of sub-microgram quantities of core material is also disclosed. | 09-02-2010 |
20100266687 | IMPROVED TABLET COATING - The present invention provides a tablet coating composition including a cellulose polymer, a plasticiser, a sweetener, and a powdered flavour composition. The powdered flavour composition includes a flavourant associated with a solid carrier. The present invention also provides a pharmaceutical tablet including a core containing an active agent and a coating formed from the tablet coating composition. | 10-21-2010 |
20100285127 | TASTE MASKED PHARMACEUTICAL COMPOSITIONS OF S-ALKYLISOTHIOURONIUM DERIVATIVES - The present invention relates to taste masked compositions of S-alkylisothiouronium derivatives, including, but not limited to, S-ethylisothiouronium diethylphosphate, in the form of a coated oral tablet having a desirable dissolution profile. | 11-11-2010 |
20100310655 | Crystal modification A of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof - The invention relates to dosage forms and formulations comprising the novel crystal modification A of the compound I-(2, 6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 Å, 5.14 Å, 4.84 Å, 4.55 Å, 4.34 Å, 4.07 Å, 3.51 Å, 3.48 Å, 3.25 Å, 3.19 Å, 3.15 Å, 3.07 Å, and 2.81 Å, determined by means of an X-ray powder pattern. Dosage forms of crystal modification A of the compound I-(2, 6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide may be for oral or parenteral administration, in the form of a solid or liquid, and in a dosage range of 20 mg to less than 500 mg. Solid dosage forms comprise a tablet or capsule, and further comprise a pharmaceutically-acceptable carrier and film-coat. | 12-09-2010 |
20110038934 | PHARMACEUTICAL COMPOSITION WITH ATORVASTATIN ACTIVE INGREDIENT - A pharmaceutical composition containing the active substance atorvastatin in the form of oblong-shaped tablets with the length of 5 to 22 mm and the width of 2 to 11 mm or round tablets with the diameter of 3 to 16 mm, the core of which is constituted of compressed granulate and contains: i. Atorvastatin and/or at least one physiologically acceptable salt thereof in the quantity of 5 to 10% by weight, related to pure atorvastatin; ii. An organic or inorganic base selected from meglumine or an alkali metal hydroxide or their combination in the quantity of 0.01 to 7% by weight; iii. A pharmaceutically acceptable filler in the quantity of 20 to 90% by weight; iv. A disintegrant in the quantity of 0.5 to 50% by weight; provided with a coat that makes up 1 to 15% of the weight of the core, the selected base being uniformly distributed in the tablet core by means of spraying the same on the solid mixture in the granule production process. The composition can be obtained by a procedure consisting of the following steps: i. Mixing a mixture of atorvastatin, a filler and a disintegrant; ii. Dissolving a base in a mixture of water and a C | 02-17-2011 |
20110104277 | OXYGEN BARRIER FILM COATINGS FOR PHARMACEUTICAL DOSAGE FORMS - A film coating which is an oxygen barrier is applied to a pharmaceutical dosage form to protect the dosage form from atmospheric oxygen. The coating comprises a polymeric binder, an anti-tackifying agent, and an optional dissolution enhancing agent, where the polymeric binder is sodium carboxymethylcellulose, the anti-tackifying agent is talc, and the optional dissolution enhancing agent is sucrose, sodium bicarbonate, or a mixture thereof. | 05-05-2011 |
20110165241 | BAZEDOXIFENE FORMULATIONS WITH ANTIOXIDANTS - This disclosure relates to pharmaceutical compositions comprising bazedoxifene and an antioxidant such as vitamin E, vitamin E TPGS, propyl gallate, citric acid, or BHA/BHT, substantially free of ascorbic acid, as well as methods of making such compositions. Also provided are methods of enhancing dissolution stability and/or enhancing bioavailability of bazedoxifene in a formulation containing an antioxidant, and methods of reducing interactions of at least one of bazedoxifene and hydroxymethyl cellulose with at least one of ascorbic acid and one or more degradant products of ascorbic acid in such compositions. | 07-07-2011 |
20120003313 | DPP IV INHIBITOR FORMULATIONS - The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus. | 01-05-2012 |
20120003314 | DELAYED-RELEASE ORAL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF COLONIC DISORDERS - A timed or delayed release oral composition delivery system for the treatment of colonic disorders and diseases is provided. According to one aspect, a delayed release oral pharmaceutical composition includes an active core comprising a therapeutically effective amount of 5-amino salicylic acid (i.e., mesalamine); a primary coating composition disposed around the active core, wherein the primary coating composition includes an enteric polymer; and a secondary coating composition disposed around the primary coating composition, wherein the secondary coating composition includes a ratio mixture of ethyl cellulose and hydroxypropyl methylcellulose. | 01-05-2012 |
20120027857 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING O-DESMETHYL-VENLAFAXINE - This invention relates to sustained release pharmaceutical compositions comprising O-desmethyl-venlafaxine, in particular to sustained pharmaceutical compositions comprising O-desmethyl-venlafaxine orotate and/or O-desmethyl-venlafaxine glucuronate. | 02-02-2012 |
20120064161 | MODIFIED RELEASE NIACIN PHARMACEUTICAL FORMULATIONS - Pharmaceutical formulations comprising niacin in a matrix comprising a hydrophobic polymer that modifies release of niacin. | 03-15-2012 |
20120064162 | DRY-COATED ORALLY-DISINTEGRATING TABLET - The purpose of the present invention is to provide a press-coated orally-disintegrating tablet characterized by containing an inner core which has an excellent disintegratability in oral cavity and a suitable hardness as a whole tablet. The present invention relates to a press-coated orally-disintegrating tablet with an outer layer surrounding an inner core wherein the inner core has a thickness in the range of 10 to 90% per that of the whole tablet, and the outer layer comprises (a) microcrystalline cellulose, (b) an inorganic excipient, and (c) one or more particular ingredients selected from the group consisting of crospovidone, starches, low substituted hydroxypropylcellulose and carmellose. | 03-15-2012 |
20120177739 | Delayed Release Tablet with Defined Core Geometry - A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released. | 07-12-2012 |
20120183615 | PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE - A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved. | 07-19-2012 |
20120225124 | STABLE LAQUINIMOD PREPARATIONS - The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3′-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide. | 09-06-2012 |
20120237602 | PRESS-COATED ORALLY-DISINTEGRATING TABLETS - The purpose of the invention is to provide a press-coated orally-disintegrating tablet having a powder/granular material with poor formability in its inner core, which has an excellent disintegrability and a suitable hardness as a whole tablet. Furthermore, the invention is a press-coated orally-disintegrating with an outer layer surrounding an inner core wherein the inner core has a thickness in the range of 30 to 80% per that of the whole tablet, and the outer layer comprises (a) microcrystalline cellulose, (b) a sugar or a sugar alcohol, and (c) one or more particular ingredients selected from the group consisting of crospovidone, starches, low-substituted hydroxypropylcellulose and carmellose. | 09-20-2012 |
20120321711 | DIRECT COMPRESSION POLYMER TABLET CORE - The present invention provides a tablet comprising a compressed tablet core which comprises at least about 80% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 80% by weight of an aliphatic amine polymer resin. The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 80% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating. | 12-20-2012 |
20120321712 | Pharmaceutical Composition - The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture. | 12-20-2012 |
20130115291 | ENTERIC TABLET - The present invention relates to an enteric tablet with improved bioavailability, which is rapidly disintegrated after reaching the intestine to allow dissolution of the active ingredient, and which characteristically reduces the amount of talc to be used and is free of an alkali component. | 05-09-2013 |
20130115292 | ENTERIC TABLET - The present invention relates to an enteric tablet with improved bioavailability, which is rapidly disintegrated after reaching the intestine to allow dissolution of the active ingredient, and which characteristically reduces the amount of talc to be used and is free of an alkali component. | 05-09-2013 |
20130122093 | FORMULATIONS OF A SRC/ABL INHIBITOR - The invention relates to pharmaceutical compositions of ′N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, and to methods of using the pharmaceutical compositions in the treatment of oncological and immunological disorders | 05-16-2013 |
20130129825 | DIVERSION-RESISTANT MICROGRANULES AND MICROTABLETS - The invention relates to the use of an oral dosage form based on microgranules and/or microtablets to reduce the abusive use of at least one active principle contained therein. The aim of the invention is to prevent the diversion of an oral dosage form based on microgranules and/or microtablets containing at least one active principle capable of causing a dependency, a gelling agent, and a gelling activator. The gelling agent and the activator are only brought into contact with each other in the event of diversion by crushing. Said judiciously selected pair of excipients confers a viscosity to the formulation, such that said formulation cannot be administered by injection or does not release the active principle rapidly by forming a gel when it comes into contact with the mucous membrane if nasally administered. | 05-23-2013 |
20130243861 | PRESS-COATED TABLETS OF PREDNISONE - The present invention provides for press-coated tablets of prednisone comprising a core comprising prednisone and a coating around the core. The present invention particularly discloses thickness of the coating applied to core having a convex shape for chronotherapeutic use. The present invention also provides for a process for preparing a press-coated tablet of prednisone and a method for treating conditions or pathology, the symptoms of which occur early in the morning. | 09-19-2013 |
20130251804 | METHOD TO IMPROVE THE SAFETY OF HANDLING OF HIGH POTENCY DRUGS IN SOLID DOSAGE FORMS WITHOUT CHANGING THEIR EFFICACY - A method to improve the safety of handling of drug substances that are dispensed as solid oral dosage forms is described that does not alter the drug-release profile and the therapeutic efficacy of the pharmaceutical product. | 09-26-2013 |
20130302419 | USE OF A PLANT EXTRACT, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF - The present invention relates to the use of a plant extract obtained from at least one plant of the Anacardiaceae family, for the preparation of a pharmaceutical composition used as a new herbal medicine for the prophylaxis and/or treatment of disorders associated with the digestive tract, and the relief of symptoms associated with these disorders. Additionally, through the scope of the present invention, the substances isolated from said extract also consist of the active ingredients of pharmaceutical compositions. A third objective of the invention is the use of said pharmaceutical compositions in the preparation of the class of herbal medicines for the prophylaxis and/or treatment of disorders associated with the digestive tract, in different stages, with posology and daily dosing. | 11-14-2013 |
20130315995 | DIRECT COMPRESSION POLYMER TABLET CORE - The present invention provides a tablet comprising a compressed tablet core which comprises at least about 80% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 80% by weight of an aliphatic amine polymer resin. The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 80% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating. | 11-28-2013 |
20130337064 | PHARMACEUTICAL COMPOSITION - To provide pharmaceutical preparation exhibiting satisfactory dissolution property in a wide pH range. | 12-19-2013 |
20130344150 | DIRECT COMPRESSION TABLETS OF OTILONIUM - This invention is related to direct compression of otilonium or its pharmaceutically acceptable salt having perfect powder flowability, good tablet weight distribution and no sticking to the punches. | 12-26-2013 |
20130344151 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING TELITHROMYCIN - The invention relates to a novel solid pharmaceutical composition of telithromycin which facilitates swallowing by the patient. | 12-26-2013 |
20140079781 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and pioglitazone, processes for the preparation thereof, and their use to treat certain diseases. | 03-20-2014 |
20140120163 | COATED TABLET FORMULATION AND METHOD - A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin | 05-01-2014 |
20140127299 | GRAS Enteric Coating Formulations and Methods of Making and Using Same - Disclosed herein are food-grade enteric coating compositions designed to release pharmaceutical and/or nutraceutical products at various regions of the intestines, wherein said compositions comprise a film former and a pore former. Also disclosed herein are methods of making and using same. | 05-08-2014 |
20140193498 | Compositions and Methods for Treating Metabolic Disorders - Compositions and methods for improving the pharmacokinetics and reducing the risk of adverse events resulting from biguanide compound administration are provided, comprising administering delayed release formulations of such compounds having a lag phase release. | 07-10-2014 |
20140212492 | Oral Enzyme Compositions for Intestinal Delivery - The present disclosure describes compositions for intestinal delivery of enzyme formulations and methods of treating health problems with these formulations. More specifically, the enzyme formulations include at least one histaminase and various methods of treatment of physical conditions, such as inflammation, allergy, histamine intolerance, and intestinal cancer. | 07-31-2014 |
20140248351 | PHARMACEUTICAL COMPOSITION COMPRISING FESOTERODINE - The present invention relates to a granulate and a pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof and stabilizer, in particular to a pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof and sucrose, polyethylene glycol, cyclodextrin, and combinations thereof and to a process for its preparation. The granulate and the pharmaceutical composition are particularly useful as a medicament, especially for the treatment of urinary incontinence. The present invention relates to use of sucrose, polyethylene glycol, cyclodextrin, and combinations thereof for stabilizing fesoterodine or a salt or a solvate thereof in a pharmaceutical composition. | 09-04-2014 |
20140271858 | COATED TABLETS OF ESZOPICLONE - Coated tablets of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are provided. The tablets minimize the perceived bitterness of the medicament. A method for analyzing instantaneous dissolution of sub-microgram quantities of core material is also disclosed. | 09-18-2014 |
20140294959 | Pharmaceutical Composition of Rosuvastatin Calcium - The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture. | 10-02-2014 |
20140302143 | Controlled Release and Taste Masking Oral Pharmaceutical Compositions - The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating. | 10-09-2014 |
20140322325 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS - A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer. | 10-30-2014 |
20140328914 | TALC-FREE POLYVINYL ALCOHOL COMPOSITION - The present invention provides a talc-free composition characterizable as non-tacky and having an average water vapor permeability of at most 5.0 times 10 | 11-06-2014 |
20140341993 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBIOTIC FROM THE QUINOLONE FAMILY AND METHOD OF PRODUCTION THEREOF - The present invention aims to provide a solid pharmaceutical composition comprising: (a) an effective antibacterial quantity of antibiotic from the quinolone family, preferably, moxifloxacin or a pharmaceutically acceptable salt thereof; and (b) a pharmacologically acceptable carrier or excipient compatible with the active ingredient, said excipient being lactose-free. | 11-20-2014 |
20140370090 | IN SITU, LIQUID-ACTIVATED FILM COATED TABLETS AND A PROCESS FOR MAKING THE SAME - Tablets and other objects are film coated by including in the tablet a film-forming polymer that is activated upon contact with an activating amount of liquid. The film-forming polymer, e.g., a cellulosic ether, is homogeneously mixed with the other ingredients of the tablet, shaped into any desirable form, loaded into a conventional coating apparatus, and sprayed or foamed with an activating amount of fluid, e.g., water, alcohol, etc., and dried. This coating process eliminates potential problems such as spray nozzle clogging, inappropriate coating fluid viscosity, and the inability to properly atomize the coating fluid. This coating process does not impart any appreciable weight or thickness gain to the tablet. | 12-18-2014 |
20140370091 | Method for Producing Aqueous Enteric Coating Liquid, Solid Preparation, and Method for Producing Same - An enteric preparation having a film-forming property and acid resistance is provided by using a simple and efficient method without using a special cooling apparatus. More specifically, provided is a method for producing an aqueous enteric coating liquid including the steps of: partially neutralizing an aqueous suspension including a cellulosic enteric material with an aqueous alkali solution, and mixing the partially-neutralized aqueous suspension with a plasticizer. Also provided is a solid preparation including a core including a drug and a coating portion obtained by coating the core with the produced aqueous enteric coating liquid. Further, provided is a method for producing a solid preparation, including respective steps in the method for producing an aqueous enteric coating liquid and a step of coating a core including a drug with the produced aqueous enteric coating liquid. | 12-18-2014 |
20140370092 | FORMULATIONS OF (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOI- SOINDOLINE-1,3-DIONE - Pharmaceutical compositions and single unit dosage forms of apremilast, i.e., (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders ameliorated by the inhibition of TNF-α production in mammals. | 12-18-2014 |
20140370093 | ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS - The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon. | 12-18-2014 |
20150056281 | Treatment of Multiple Sclerosis With Combination of Laquinimod and Interferon-Beta - This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod as an add-on therapy to or in combination with interferon-β. This invention also provides a package and a pharmaceutical composition comprising laquinimod and interferon-β for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with interferon-β in treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and interferon-β in the preparation of a combination for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. | 02-26-2015 |
20150079171 | EASILY ADMINISTRABLE SOLID PREPARATION - It is an object to provide a coating composition, which is used for an orally-administered preparation, the administering property of which has been improved, and/or an easily administrable preparation that does not affect dissolution property. The aforementioned object can be achieved using a coating composition comprising a first thickener selected from the group consisting of a carboxyvinyl polymer and sodium alginate, a polyvalent metal compound, and at least one type of a second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate, with the proviso that when the first thickener is sodium alginate the second thickener is not sodium alginate, or using a coating composition comprising, as thickeners, hydroxypropylmethylcellulose and sugar or sugar alcohol having a solubility at 20° C. of 30 or more. | 03-19-2015 |
20150093439 | COMPRESSION COATED PULSATILE RELEASE COMPOSITIONS - The present invention is directed to a dosage form comprising an immediate release portion of a first active pharmaceutical ingredient and a delayed release portion of a second active pharmaceutical ingredient wherein (a) the immediate release portion comprises from about 1 mg to about 1000 mg of the first active pharmaceutical ingredient; and (b) the delayed release portion comprises from about 1 mg to about 1000 mg of the second active pharmaceutical ingredient; wherein the delayed release portion is coated with a delayed release coating comprising at least one swellable erodible polymer and a filler, and wherein the immediate release portion is in contact with the delayed release coating. | 04-02-2015 |
20150125527 | PHARMACEUTICAL ADMINISTRATION FORMS COMPRISING 5-CHLORO-N-(METHYL)-2-THIOPHENECARBOXAMIDE - The present invention relates to solid orally administrable pharmaceutical administration forms comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (rivaroxaban, active compound (I)), characterized in that a partial amount of the active compound (I) is released rapidly and a partial amount is released in a controlled manner (modified, retarded, delayed), and to processes for their preparation, their use as medicaments and their use for the prophylaxis, secondary prophylaxis or treatment of disorders. | 05-07-2015 |
20150320749 | IMMEDIATE RELEASE 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imida- zol-1-yl)-3-(trifluoromethyl)phenyl] benzamide FORMULATION - A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1 H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed | 11-12-2015 |
20150342938 | PHARMACEUTICAL COMPOSITION - To provide pharmaceutical preparation exhibiting satisfactory dissolution property in a wide pH range. | 12-03-2015 |
20150352128 | CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITION - Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. | 12-10-2015 |
20150368366 | NOVEL ESTERIFIED CELLULOSE ETHERS OF VERY HIGH MOLECULAR WEIGHT - Esterified cellulose ethers which comprise (i) groups of the formula —C(O)—R—COOA or (ii) a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA, wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, which have a viscosity of up 50 mPa·s, measured as a 10 wt % solution of the esterified cellulose ether in acetone at 20° C., and a weight average molecular weight M | 12-24-2015 |
20150374632 | ENTERIC COATED TABLET - To provide an enteric coated tablet containing a large amount of medicinal ingredient and having sufficient impact resistance, without forming a thick enteric coating layer. | 12-31-2015 |
20160015644 | GASTRO-RETENTIVE SUSTAINED-RELEASE ORAL DOSAGE FORM OF A BILE ACID SEQUESTRANT - Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant dispersed in a polymeric matrix. The bite acid sequestrant composition may be administered alone or in combination with at least one proton pump inhibitor, and optionally one or more agents chosen from antacids, histamine H | 01-21-2016 |
20160022667 | PYRROLOQUINOLINYL-PYRROLIDINE-2,5-DIONE FORMULATIONS AND METHODS FOR PREPARING AND USING SAME - The present invention provides pyrroloquinolinyl-pyrrole-2,5-dione formulations and methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of the formulations containing pyrroloquinolinyl-pyrrole-2,5-dione compounds. | 01-28-2016 |
20160082009 | PHARMACEUTICAL PREPARATION COMPRISING PHENYLALANINE DERIVATIVE - The disclosed pharmaceutical preparation comprises a compound represented by the chemical formula (A) or a pharmaceutically acceptable salt thereof, which is dispersed in a matrix consisting of a water-soluble high molecular weight substance; and Crospovidone: | 03-24-2016 |
20160089381 | STABILITY OF PROGESTOGEN FORMULATIONS - In a preparation for hormone replacement therapy having a low content of progestogen, the stability of the progestogen component can be enhanced by using a cellulosic binder, for example hydroxypropylcellulose, in stead of a non-cellulosic binder. | 03-31-2016 |
20160101056 | MUCOADHESIVE DEVICES FOR DELIVERY OF ACTIVE AGENTS - Described herein are systems and methods for transmucosal delivery of active agents. In some embodiments, a system may comprise one or more mucoadhesive devices configured for release of an active agent. | 04-14-2016 |
20160166510 | STABILIZED PROLONGED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING ATYPICAL ANTIPSYCHOTIC | 06-16-2016 |
20160199307 | COATING AGENT COMPRISING HYDROXYALKYL CELLULOSE | 07-14-2016 |
20170231988 | Pharmaceutical Composition of Rosuvastatin Calcium | 08-17-2017 |